<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04766476</url>
  </required_header>
  <id_info>
    <org_study_id>MB006-025</org_study_id>
    <nct_id>NCT04766476</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and drug levels of&#xD;
      BMS-963272 compared to placebo in participants with nonalcoholic fatty liver disease (NAFLD)&#xD;
      and high probability of advanced fibrosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 29, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Up to 166 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>Up to 166 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Blood pressure</measure>
    <time_frame>Up to 166 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Heart rate</measure>
    <time_frame>Up to 166 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in physical examination findings</measure>
    <time_frame>Up to 166 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: PR interval</measure>
    <time_frame>Up to 166 days</time_frame>
    <description>PR interval: The time from the onset of the P wave to the start of the QRS complex</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QRS interval</measure>
    <time_frame>Up to 166 days</time_frame>
    <description>QRS interval: A combination of the Q wave, R wave and S wave, the &quot;QRS complex&quot; represents ventricular depolarization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QT interval</measure>
    <time_frame>Up to 166 days</time_frame>
    <description>QT interval: Measured from the beginning of the QRS complex to the end of the T wave</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QTcF interval</measure>
    <time_frame>Up to 166 days</time_frame>
    <description>QTcF interval: Corrected QT interval using Fridericia's formula (QTcF)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry test</measure>
    <time_frame>Up to 166 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Hematology tests</measure>
    <time_frame>Up to 166 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Coagulation tests</measure>
    <time_frame>Up to 166 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests</measure>
    <time_frame>Up to 46 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Liver function tests</measure>
    <time_frame>Up to 166 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Lipid panel tests</measure>
    <time_frame>Up to 166 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) sampling: Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Day 1 and Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) sampling: Time to maximum observed plasma concentration (Tmax)</measure>
    <time_frame>Day 1 and Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) sampling: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC [0-T])</measure>
    <time_frame>Day 1 and Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration (Ctrough)</measure>
    <time_frame>Day 1, Day 15, Day 29, Day 57, and Day 84</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Nonalcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Active Treatment (BMS-963272) Dosing Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Treatment (BMS-963272) Dosing Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-963272</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Active Treatment (BMS-963272) Dosing Regimen 1</arm_group_label>
    <arm_group_label>Active Treatment (BMS-963272) Dosing Regimen 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo matching BMS-963272</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) ≥ 30 kg/m^2&#xD;
&#xD;
          -  Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) ≥ 10% as evaluated&#xD;
             by central review&#xD;
&#xD;
          -  FibroScan-based transient elastography ≥ 9.9 kPa&#xD;
&#xD;
          -  Alanine aminotransferase (ALT): &gt; 30 U/L&#xD;
&#xD;
          -  If available, historical diagnosis of non-alcoholic steatohepatitis (NASH) according&#xD;
             to NASH Clinical Research Network classification by liver biopsy within 6 months&#xD;
             before screening will be recorded&#xD;
&#xD;
          -  Must agree to follow specific methods of contraception, if applicable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are breastfeeding&#xD;
&#xD;
          -  Inability to tolerate the mixed meal or the testing conditions, oral medication,&#xD;
             venipuncture and/or inadequate venous access&#xD;
&#xD;
          -  History or current diagnosis of cirrhosis, hepatocellular carcinoma (HCC), or hepatic&#xD;
             decompensation&#xD;
&#xD;
          -  Recent history (within 2 years before screening) of drug or alcohol abuse or excessive&#xD;
             alcohol intake, defined as 30 g/day (men) or 20 g/day (women)&#xD;
&#xD;
          -  Use of lipase inhibitors such as orlistat within 4 weeks before screening or during&#xD;
             screening&#xD;
&#xD;
          -  Use of glucagon-like peptide-1 (GLP-1) receptor agonists within 12 weeks before&#xD;
             screening or during screening&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic blood pressure &gt; 160 mmHg and/or diastolic blood&#xD;
             pressure &gt; 100 mmHg) during screening, unless discussed with the Medical Monitor&#xD;
&#xD;
          -  Glycated hemoglobin (HbA1c) ≥ 9.5%&#xD;
&#xD;
          -  NASH-modifying therapies including investigational therapies (e.g., obeticholic acid,&#xD;
             ursodeoxycholic acid) within 90 days before screening or during screening&#xD;
&#xD;
          -  Medications for obesity within 12 weeks before screening, or during screening&#xD;
&#xD;
          -  If taking vitamin E at a dose ≥ 800 mg/day, the dose must be stable beginning at least&#xD;
             6 months before screening and should remain stable during screening&#xD;
&#xD;
          -  If taking a thiazolidinedione, the dose must be stable beginning at least 12 weeks&#xD;
             before screening and should remain stable during screening&#xD;
&#xD;
          -  If taking a dipeptidyl peptidase (DPP)-4 inhibitor or other medications for diabetes,&#xD;
             the dose must be stable beginning at least 12 weeks before screening and should remain&#xD;
             stable during screening&#xD;
&#xD;
          -  If taking insulin, the dose may be altered by up to 10% within 12 weeks before&#xD;
             screening and during the screening period&#xD;
&#xD;
          -  If taking a statin or other prescription or over-the-counter lipid-lowering drug, the&#xD;
             dose must be stable beginning at least 6 weeks before screening and should remain&#xD;
             stable during screening&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cullman Clinical Trials</name>
      <address>
        <city>Cullman</city>
        <state>Alabama</state>
        <zip>35058</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randall Quinn, Site 0021</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arizona Liver Health - Chandler</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Kohli, Site 0011</last_name>
      <phone>4804704000313</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arizona Liver Health - Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naim Alkhouri, Site 0018</last_name>
      <phone>48047040005204854000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0005</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33434</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0017</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0023</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Floridian Clinical Research</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Sanchez, Site 0022</last_name>
      <phone>3053309977115</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Carlos Rondon, Site 0002</last_name>
      <phone>305-817-2900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Pharma - Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33147</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Cruz, Site 0001</last_name>
      <phone>3052202727805</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0016</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bastrop</city>
        <state>Louisiana</state>
        <zip>71220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0025</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Diabetes and Obesity Research Institute</name>
      <address>
        <city>Biloxi</city>
        <state>Mississippi</state>
        <zip>39532</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Farrow, Site 0020</last_name>
      <phone>228-831-8764</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Kansas City Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradley Freilich, Site 0007</last_name>
      <phone>816-759-5274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ClinSearch</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark McKenzie, Site 0003</last_name>
      <phone>423-698-4584</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastro One - Germantown Office - Wolf Park Drive</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ziad Younes, Site 0019</last_name>
      <phone>901-309-6035</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pinnacle Clinical Research - Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78757</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadege Gunn, Site 0008</last_name>
      <phone>512-384-1560</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Texas Research Institute</name>
      <address>
        <city>Edinburg</city>
        <state>Texas</state>
        <zip>78539</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rashmee Patil, Site 0014</last_name>
      <phone>40965664759562846353</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0013</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Liver Institute/American Research Corporation</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Lawitz, Site 0004</last_name>
      <phone>210-918-8854</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Pinnacle Clinical Research - San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madhavi Rudraraju, Site 0009</last_name>
      <phone>210-982-0320</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0012</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BMS-963272</keyword>
  <keyword>Liver Fibrosis</keyword>
  <keyword>Nonalcoholic Fatty Liver Disease (NAFLD)</keyword>
  <keyword>Nonalcoholic Steatohepatitis (NASH)</keyword>
  <keyword>Phase 1b</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

